AGL 6.70 Decreased By ▼ -0.08 (-1.18%)
ANL 9.75 Increased By ▲ 0.37 (3.94%)
AVN 80.00 Decreased By ▼ -1.40 (-1.72%)
BOP 5.45 Decreased By ▼ -0.02 (-0.37%)
CNERGY 4.95 Decreased By ▼ -0.08 (-1.59%)
EFERT 81.82 Decreased By ▼ -1.17 (-1.41%)
EPCL 59.27 Increased By ▲ 0.32 (0.54%)
FCCL 15.64 Decreased By ▼ -0.16 (-1.01%)
FFL 6.56 Increased By ▲ 0.06 (0.92%)
FLYNG 8.35 Decreased By ▼ -0.12 (-1.42%)
GGGL 10.20 Decreased By ▼ -0.03 (-0.29%)
GGL 16.45 Decreased By ▼ -0.19 (-1.14%)
GTECH 8.54 Decreased By ▼ -0.06 (-0.7%)
HUMNL 6.35 Decreased By ▼ -0.10 (-1.55%)
KEL 3.00 Decreased By ▼ -0.05 (-1.64%)
LOTCHEM 30.50 Increased By ▲ 0.62 (2.07%)
MLCF 28.90 Increased By ▲ 0.10 (0.35%)
OGDC 75.45 Decreased By ▼ -0.90 (-1.18%)
PAEL 16.28 Decreased By ▼ -0.07 (-0.43%)
PIBTL 5.73 Decreased By ▼ -0.05 (-0.87%)
PRL 17.23 Decreased By ▼ -0.22 (-1.26%)
SILK 1.13 Decreased By ▼ -0.03 (-2.59%)
TELE 11.74 Increased By ▲ 0.34 (2.98%)
TPL 8.01 Decreased By ▼ -0.16 (-1.96%)
TPLP 21.65 Decreased By ▼ -0.60 (-2.7%)
TREET 23.40 Decreased By ▼ -0.18 (-0.76%)
TRG 144.50 Decreased By ▼ -3.50 (-2.36%)
UNITY 23.15 Decreased By ▼ -0.20 (-0.86%)
WAVES 11.52 Decreased By ▼ -0.18 (-1.54%)
WTL 1.61 Increased By ▲ 0.02 (1.26%)
BR100 4,244 Decreased By -4.4 (-0.1%)
BR30 16,406 Decreased By -179.2 (-1.08%)
KSE100 42,107 Decreased By -53.1 (-0.13%)
KSE30 15,869 Decreased By -25.5 (-0.16%)
Follow us

Merck & Co Inc and partner Ridgeback Biotherapeutics said on Friday six lab studies showed their experimental oral COVID-19 drug molnupiravir was active against the fast-spreading Omicron variant.

The data evaluated the antiviral activity of molnupiravir and other COVID-19 antiviral agents against COVID-19 variants of concern. Molnupiravir is yet to be studied against Omicron in human studies, the companies said.

Molnupiravir and a rival oral pill from Pfizer Inc were authorized in the United States in December and are considered as important tools against Omicron.

Merck expects COVID-19 pill molnupiravir to be effective against Omicron

Pfizer said in December lab data suggested its drug Paxlovid retained its effectiveness against Omicron.

Merck said earlier this month its pill has a mechanism that can work against Omicron and any other variant.

Molnupiravir has been authorized for use in more than 10 countries, including the United States, United Kingdom and Japan.

Comments

Comments are closed.